MedTrace Logo

Intravenous Bisphosphonate in Stress Fracture Treatment -A Randomised Controlled Double Blinded Multicenter Trial

NCT03576599 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-09-13

No results posted yet for this study

Summary

The effect of an intravenous bisphosphonate (zoledronic acid) on healing and symptoms of stress fractures that do not respond to conservative/conventional treatment within 6 months, will be investigated.

Conditions

  • Stress Fracture Foot
  • Stress Fracture Ankle

Interventions

DRUG

Zoledronic Acid Injectable Product

One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Betanien Hospital

    collaborator OTHER

  • Sykehuset Ostfold

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Elisabeth E Husebye, PhD · Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-29
Primary Completion
2019-06-26
Completion
2019-06-26

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03576599 on ClinicalTrials.gov